An infectious disease (ID) consultation within 12 hours of presenting to the emergency department (ED) with severe sepsis and septic shock (SS/SS) may lower mortality risk, a recent retrospective study showed.
Dr. Kubi Appiah, Dr. Piya Chaemsaithong, Dr. Liona Chiu Yee Poon, 20191129085839
Preterm birth (PTB) is birth that occurs before 37 weeks’ gestation, and it is a leading cause of perinatal morbidity and mortality.1 Babies born before 34 weeks’ gestation are particularly associated with high rates of morbidity and mortality.2 They are also at risk of long-term medical and social sequelae.3 It is therefore important to institute preventative measures that can help mitigate the occurrence of PTB in pregnant women.
Rivaroxaban treatment after successful transcatheter aortic valve replacement (TAVR) for aortic valve stenosis is linked to an increased risk of death, thromboembolic events, and bleeding in patients without an indication for oral anticoagulation, results of the GALILEO* trial showed.
Childhood cancer survivors who were treated with radiotherapy and anthracyclines may have an elevated risk of developing subsequent breast cancer, according to an analysis of patients in the North American Childhood Cancer Survivor Study.
The anti-inflammatory drug colchicine at a dose of 0.5 mg/day significantly reduced the risk of ischaemic cardiovascular (CV) events in individuals with a recent myocardial infarction (MI), according to results of the COLCOT* trial presented at AHA 2019.
Use of the PCSK9* inhibitor alirocumab in acute coronary syndrome (ACS) patients on a background of high-intensity statin treatment delivers reductions in total hospitalizations and death with corresponding gains in days alive and out of hospital (DAOH), according to the results of prespecified and posthoc analyses of the ODYSSEY OUTCOMES** trial presented at the American Heart Association (AHA) 2019 Scientific Sessions.
Treatment with the PCSK9 inhibitor alirocumab reduces the risk of stroke in patients with recent acute coronary syndrome (ACS) and dyslipidaemia despite intensive statin therapy, regardless of their baseline low-density lipoprotein cholesterol (LDL-C) and history of cerebrovascular disease (CeVD), according to the results of the ODYSSEY OUTCOMES trial presented at the 2019 Scientific Sessions of the American Heart Association.
The combination of pomalidomide and dexamethasone (PomDex) is effective against relapsed/refractory multiple myeloma (MM) in Asians, according to a recent study. The addition of cyclophosphamide may further supplement its effects.
New drug applications approved by US FDA as of 16 - 30 November 2018
which includes New Molecular Entities (NMEs) and new biologics. It does
not include Tentative Approvals. Supplemental approvals may have
occurred since the original approval date.
Elvira Manzano, Roshini Claire Anthony,
01 Oct 2019
The European Society of Cardiology (ESC) has released five new guidelines at the ESC Congress 2019, recommending an even lower LDL-C* target in patients at very high risk for cardiovascular disease (CVD), and the use of SGLT2** inhibitors and GLP-1*** receptor agonists as first-line treatments in those with diabetes to reduce their CVD risk.
Five years of extended therapy with the aromatase inhibitor (AI) letrozole did not improve survival in postmenopausal breast cancer patients, according to findings of the NRG Oncology/NSABP B-42 trial presented at the San Antonio Breast Cancer Symposium (SABCS 2016) held in Texas, US.